BET family protein degraders poised to join the senolytic arsenal
Sign Up to like & getrecommendations! Published in 2020 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-020-0202-2
Abstract: In a recent study published in Nature Communications, Wakita et al. identified BET family protein degrader (BETd) as a novel senolytic drug through high-throughput screening and biofunctional assays. BETd preferentially eliminated senescent cells by targeting… read more here.
Keywords: senescent cells; treatment; bet family; arv825 treatment ... See more keywords